# US 2019/0054100 A1 · Medicament for treatment of diabetic foot infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054100 A1
- Document ID: US20190054100A1
- Status: Published application
- Kind: A1
- Application number: 16/079,804
- Filed: 2017-02-27
- Published: 2019-02-21
- Earliest claimed: 2016-02-26
- Assignees: Debiopharm International S.A.
- Applicants: Debiopharm International S.A.
- Inventors: Grégoire Vuagniaux; Linda Kadi; Frederick Wittke
- Web page: https://patentgrep.com/patent/US20190054100A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides means and methods for treating diabetic foot infections. In particular, drug compounds are provided that combine a high therapeutic activity against Staphylococcus Spp. bacteria with a high degree of bone penetration and vasodilatory effects. This unique combination of properties allows to accomplish high local concentrations of the drug at the site of infection even in diabetic foot patients typically having poor blood perfusion at the site of infection.

## Claims

### Claim 1

A method of treating diabetic foot-associated bacterial infections or other bacterial infections of the foot associated with peripheral ischemia in a patient, comprising administering to the patient an effective amount of a compound, wherein the compound is {6-[(1E)-3-{methyl[(3-methyl-1-benzofuran-2-yl)methyl]amino}-3-oxoprop-1-en-1-yl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl}methyl dihydrogen phosphate or a pharmaceutically acceptable salt or metabolite or pharmaceutically acceptable salt of a metabolite thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the bacterial infection is caused by a Staphylococcal species including but not limited to Staphylococcus aureus.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the bacterial infection is caused by methicillin-resistant Staphylococcus aureus.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the bacterial infection is an infection of soft tissue and/or bone tissue.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the bacterial infection is osteomyelitis.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound is the bis-ethanolammonium salt of (6-[(1E)-3-{methyl[(3-methyl-1-benzofuran-2-yl)methyl]amino)-3-oxoprop-1-en-1-yl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl}methyl dihydrogen phosphate.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound is administered at a dosage of 5 mg/day to 600 mg/day, preferably 40 mg/day to 720 mg/day, more preferably 80 mg/day to 480 mg/day, most preferably 16 mg/day to 480 mg/day.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the compound is administered intravenously twice daily, each administration being in a dosage of 40 mg to 160 mg.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the compound is administered orally twice daily, each administration being in a dosage of 40 mg to 240 mg.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the compound is administered intravenously three times daily, each administration being in a dosage of 40 mg to 240 mg.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the compound is administered orally three times daily, each administration being in a dosage of 40 mg to 240 mg

### Claim 12 (depends on 1)

The method according to claim 1, wherein the method comprises a surgical procedure to remove infected and/or necrotic tissue prior to, simultaneously with and/or after administration of said compound.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the method comprises administration of one or more further antibiotic agents or antibacterial agents.

### Claim 14 (depends on 1)

A pharmaceutical composition, wherein the composition comprises the compound specified in claim 1.

### Claim 15 (depends on 6)

The method according to claim 6, wherein the bacterial infection is caused by a Staphylococcal species including but not limited to Staphylococcus aureus.

### Claim 16 (depends on 6)

The method according to claim 6, wherein the bacterial infection is an infection of soft tissue and/or bone tissue.

### Claim 17 (depends on 6)

The method according to claim 6, wherein the bacterial infection is osteomyelitis.

### Claim 18 (depends on 6)

The method according to claim 6, wherein the method comprises a surgical procedure to remove infected and/or necrotic tissue prior to, simultaneously with and/or after administration of said compound.

### Claim 19 (depends on 6)

The method according to claim 6, wherein the method comprises administration of one or more further antibiotic agents or antibacterial agents.

### Claim 20 (depends on 6)

A pharmaceutical composition, wherein the composition comprises the compound specified in claim 6.
